Bristol Myers Squibb  4Q Revenues: $11.4 billion (-5%) 4Q Earnings: $2.0 billion (-15%) YTD Revenues: $46.2 billion (0%) YTD Earnings: $6.3 billion (-10%) Comments: Results in the quarter were impacted by loss of exclusivity for primarily Revlimid and foreign exchange impacts, partially offset by Opdivo and new product portfolio sales.  Revenues for in-line products were $8.3 billion in the quarter, up 4%, driven by:   Eliquis revenues grew 1% to $2.7 billion. U.S. revenues were $1.7 bil...